

23 May 2023

Usage of high-cost drugs in ophthalmology

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition?

Aflibercept	4430
Bevacizumab	4
Brolucizumab	0
Dexamethasone	22
Faricimab	0
Ranibizumab	1282

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept	167
Bevacizumab	0
Brolucizumab	0
Dexamethasone	9
Faricimab	0
Ranibizumab	25